BioStock: Arcede Pharma’s RCD405 well tolerated

Lund-based Arcede Pharma is working hard to complete the preclinical work on the drug candidate RCD405. The company now reports the first part of the toxicological program and notes that the substance is well tolerated. BioStock contacted the company’s CEO Mia Lundblad to find out more about what this means for the project and about the next step.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/arcede-pharmas-rcd405-well-tolerated/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se